

MEDIA STATEMENT

Date: August 26, 2025

Monroe County Council Advances Tax Abatement for Simtra BioPharma Solutions Expansion

On Tuesday, August 26, the Monroe County Council voted to approve Simtra BioPharma Solutions' request for a tax abatement to support the development of a newly acquired **65-acre site** near Bloomington, Indiana. The expansion will boost U.S. manufacturing capacity for sterile injectable medicines and create high-quality jobs in Monroe County, Indiana. The request now moves to the Monroe County Commissioners for final consideration on Thursday, August 28.

Simtra [announced the purchase of the property](#) on July 25, 2025. The site includes more than 300,000 sq. ft. of available space for expansion under-roof. Plans include an initial **\$241 million capital investment**, to purchase, prepare and equip the facility with its first manufacturing line. Each additional manufacturing line would require approximately another **\$100 million** investment. Each line is expected to create **90 jobs** with an **average annual compensation of \$70,000**. This project is in addition to [the \\$250+ million construction project](#) currently underway at Simtra's existing manufacturing site.

"This investment strengthens our ability to deliver critical, life-changing injectable medicines for our customers' patients and reinforces our commitment to Bloomington as a hub for advanced pharmaceutical manufacturing," said Pat Adams, Site Director, Bloomington. *"We are grateful for the Monroe County Council's support and look forward to the opportunities this expansion brings to our employees, community, and customers."*

The project underscores Simtra's commitment to meeting growing demand for injectable medicines in the U.S. and globally, while contributing to the local economy through high-paying jobs and long-term investment.

PROJECT FACTS

Property Size	65 acres
Developable Space	300,000 – 400,000 sq. ft.
Initial Capital Investment Commitment	\$241 million (purchase, demo, first manufacturing line)

Investment per Manufacturing Line	~\$100 million
Jobs per Line	~90
Average Compensation	\$70,000/year
Potential Additional Investment by December 31, 2035	\$200 million* (dependent on market demand)

About Simtra BioPharma Solutions

Simtra BioPharma Solutions is a leading contract development and manufacturing organization (CDMO) specializing in sterile injectable products. With facilities in the U.S. and Germany, Simtra partners with pharmaceutical companies worldwide to deliver medicines that bring life-changing products to patients.

For more information on the property purchase announcement, visit www.simtra.com

Media Contact:

Rhonda Luniak
Director, Communications
303.406.8743
rjluniak@simtra.com